CPSE:GMABBiotechs
Genmab (CPSE:GMAB) Valuation Check After Q1 2026 Net Income Fall And Share Price Weakness
Genmab (CPSE:GMAB) has drawn fresh attention after its first quarter 2026 report, where sales reached US$896 million but net income dropped to US$53 million, alongside a negative immediate share price reaction.
See our latest analysis for Genmab.
The weak 1 day share price return of 6.74% and 30 day share price return of 8.30% follow a Q1 update where revenue moved higher but net income declined sharply, leaving the current share price at DKK1,640. Over a longer horizon, the 1 year total...